CEO Interview

Ventripoint Diagnostics (TSX. V: VPT) (OTC: VPTDF) AI-driven medical imaging technology for cardio and cancer markets

                  Ventripoint Diagnostics (TSX. V: VPT) (OTC: VPTDF) interview with Dr. George Adams, CEO, discussing the company’s innovative AI-driven medical imaging technology addressing the cardio and cancer markets. […]

CEO Interview

Trendlines Group, Ltd.  (OTC: TRNLY) Delivering 10X returns on Israeli medical and agricultural innovation

              Trendlines Group, Ltd.  (OTC: TRNLY) (Singapore: 42T), interview with co-CEO/Chairman Steve Rhodes, discussing the company’s investment strategy in early-stage medical and agricultural innovation companies in Israel and Singapore. Since […]

CEO Interview

BrainStorm Cell Therapeutics (NASDAQ: BCLI) Stem cell therapy for ALS in Phase III FDA trials

      BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) interview with CEO, Chaim Lebovits, discussing the company’s advancements in developing stem cell therapies to treat neurodegenerative diseases. The company’s pipeline includes a lead indication for ALS- Amyotrophic Lateral […]

CEO Interview

Pluristem Therapeutics, Inc. (NASDAQ: PSTI) Regenerative medicine technologies for billion dollar markets

            Pluristem Therapeutics, Inc. (NASDAQ: PSTI), interview with co-CEO Yaky Yanay. Yaky explains Pluristem’s regenerative medicine technologies, which use placenta-derived cell products, and address multi-billion health markets. Pluristem has 3 […]


Pulmatrix (NASDAQ: PULM) Investor Presentation

Pulmatrix (NASDAQ: PULM) Investor Presentation 9/5/2018 . . . This content is available to members only. If you are an existing member, please LOGIN Note a member? Sign up  and get immediate access. $195 quarterly (90 […]


Check-Cap (NASDAQ: CHEK) Announces Pricing of $17.5 Million Upsized Underwritten Public Offering

ISFIYA, Israel, May 04, 2018 — Check-Cap Ltd. (the “Company” or “Check-Cap”) (NASDAQ: CHEK, CHEKW, CHEKZ), a clinical-stage medical diagnostics company engaged in the development of C-Scan®, an ingestible capsule for preparation-free, colorectal cancer screening, […]


Abeona Therapeutics (NASDAQ:ABEO) Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten Disease

NEW YORK and CLEVELAND, April 20, 2018 – Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, announced today that the European […]